Chemoresistance: Impact of nuclear factor (NF)-κB inhibition by small interfering RNA

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3262-3264

  Veiby, Ole Petter ^a   Read, Margaret A ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PROTEIN SUBUNIT; RNA; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR;

CANCER RESISTANCE; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; NONHUMAN; NOTE; NUCLEAR LOCALIZATION SIGNAL; PHOSPHORYLATION; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; DNA DAMAGE; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NF-KAPPA B; RNA, SMALL INTERFERING;

EID: 2542449069     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0703     Document Type: Note

References (29)

1. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
2. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
3. Biswas DK, Dai SC, Cruz A, et al. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 2001;98:10386-91.
4. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999;59:3495-504.
5. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
6. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-kappa B is upregulated in colorectal cancer Surgery (St Louis) 2001;130:363-9.
7. Liptay S, Weber CK, Ludwig L, et al. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
8. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
9. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001;115:279-86.
10. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52:183-200.
11. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001;61:4901-9.
12. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
14. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
15. Kato T Jr, Delhase M, Hoffmann A, Karin M. CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 2003;12:829-39.
16. rsk signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004;24:1823-35.
17. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 2003;12:15-25.
18. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (Wash DC) 1996;274:784-7.
19. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-7.
20. Cusack JC Jr, Liu R, Baldwin AS Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation Cancer Res 2000;60:2323-30.
21. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference mediated down-regulation of the NF-kB p65 subunit. Clin Cancer Res 2004;10:3333-3341.
22. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl):S81-96.
23. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-83.
24. Kalota A, Shetzline SE, Gewirtz AM. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol Ther. In press 2004.
25. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet 2003;362:1401-3.
26. Kane, RC, Bross PF, Farrell AT, Pazdur R. Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 2003;8:508-13.
27. Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
28. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003;8:307-15.
29. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.